Analysts Set Expectations for Altimmune FY2029 Earnings

Altimmune, Inc. (NASDAQ:ALT) – Investment analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Altimmune in a research note issued on Wednesday, January 22nd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $1.30 for the year. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The firm had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period in the prior year, the business posted ($0.39) earnings per share.

Several other equities research analysts have also recently issued reports on the stock. UBS Group initiated coverage on shares of Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective for the company. Stifel Nicolaus initiated coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $20.83.

Altimmune Trading Down 1.0 %

Shares of ALT opened at $6.93 on Monday. The firm has a fifty day moving average price of $7.87 and a 200-day moving average price of $7.19. The firm has a market capitalization of $492.86 million, a P/E ratio of -4.47 and a beta of 0.22. Altimmune has a 12-month low of $5.28 and a 12-month high of $14.84.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bellevue Group AG boosted its stake in Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after acquiring an additional 263,660 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Altimmune in the 3rd quarter worth $674,000. Barclays PLC grew its stake in Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after buying an additional 75,064 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Altimmune by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after buying an additional 4,772 shares in the last quarter. Finally, Stifel Financial Corp boosted its holdings in Altimmune by 77.4% in the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock worth $109,000 after acquiring an additional 7,746 shares in the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.